ANI PharmaceuticalsANIP
Recorded

ANI Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanBiopharma Analyst

Joining us again for this year's Guggenheim Healthcare Innovation Conference. I am Vamil Divan, one of the biopharma analysts here at Guggenheim. Joined from the Guggenheim side on the stage by Daniel Krizay, one of the members of the team as well. Next up from the company side in this room, we have ANI Pharmaceuticals. Thanks so much for joining us. We have Nikhil Lalwani next to me, the CEO of the company. Stephen Carey next to him, the CFO. Exciting times at ANI. You just reported earnings, you reported acquisition in the last few days here.

Vamil DivanBiopharma Analyst

Maybe Nikhil, just to kind of kick things off, for those less familiar with the story, just give a little bit of background of the ANI story and kind of the evolution of the company over the last year or so, and then we will dive into some of the details after that.

Nikhil LalwaniCEO

Sure. Good afternoon, everybody, and thank you for joining us. Yeah, we have had an exciting year with accelerating our transformation into a leading rare disease company. As a reminder, we have two strong growth, durable assets, increasingly profitable in our rare disease franchise that both have operate in Cortrophin and ILUVIEN. They both operate in large addressable markets that are significantly under-penetrated, so giving strong multi-year growth opportunity. They have durability because Cortrophin is tough to genericize and has IP that goes until 2043, and ILUVIEN has high barriers to genericization, so there is durability.

Nikhil LalwaniCEO

As you alluded to, we are thrilled to announce the addition of EMCITATE through the acquisition of Egetis Therapeutics, another rare disease asset that expands the scope and scale of our rare disease business, adds an asset with $300 million plus in peak sales, and leads us further in our rare disease journey, where by the end of this decade, a substantial majority of our sales will come from rare disease. We are already at over 50% in this year. We will also improve the operating margin profile and the growth profile of the company's rare disease business. All in all, a great part of the ANI's rare disease journey.

Vamil DivanBiopharma Analyst

Okay, great. So why don't we start with that, and I know you're probably limited on what you can share, just given the deal's still going through the process. But the acquisition, maybe the strategic and the financial rationale for doing the acquisition, and then why Egetis specifically?

Nikhil LalwaniCEO

Sure. So strategically, the acquisition of Egetis Therapeutics plays a key role in expanding the scope and scale of our rare disease business. We have been monitoring the Your mic is off. Oh, it's off? Your mic is off. Oh. Sorry. You want me to start again?

Nikhil LalwaniCEO

Yeah, that's Do you want us to redo the previous questions?

Vamil DivanBiopharma Analyst

Was it still picking up? It was okay? I got picked up.

Vamil DivanBiopharma Analyst

It was still getting picked up.

Nikhil LalwaniCEO

Okay, sorry. No, no. Yeah.

Nikhil LalwaniCEO

Coming back to the Egetis acquisition and the strategic and financial rationale for the same, which was your question. Number one, it expands the scope and scale of our rare disease business. EMCITATE is a first-in-class drug. It's the only approved treatment for the treatment of peripheral thyrotoxicosis for patients that are impacted by MCT8 deficiency. MCT8 deficiency is a debilitating condition that impacts patients from birth, with median mortality of 35 years. Caregivers need to give 24/7 care to patients, and EMCITATE is the first and only approved FDA treatment for this indication. It's also approved in Europe and has been launched in Germany. Even beyond this, strategically, it also helps us on our purpose of serving patients, improving lives, because it brings an FDA-approved treatment, first and only of its type, to an indication for which there is no approved therapy.

Nikhil LalwaniCEO

It also leverages our rare disease expertise and infrastructure, and brings ANI resources to expand the reach of EMCITATE to the patients in need, appropriate patients in need. It adds the capability strategically of research and development, right? It strengthens our capability in the R&D team that got EMCITATE approval for thyrotoxicosis for patients with MCT8 deficiency are also working on EMCITATE for RTH beta, which is an additional pipeline indication. So it brings that capability in-house. From a financial perspective, it adds an asset with $300 million plus in peak sales, a much more improved operating margin profile than our two existing assets. And overall, financially, it also makes a ton of sense for the company to expand.

Nikhil LalwaniCEO

As I said, towards the end of this decade, with the addition, now we will have three rare disease assets, and the operating margin profile of the company and the growth and durability of all three assets is substantial. EMCITATE has patents that grow until 2045, so just a significant runway for growth too.

Vamil DivanBiopharma Analyst

Okay. Then maybe just last question on this is just the next steps here in terms of getting the deal closed.

Nikhil LalwaniCEO

Sure. I think first and foremost, the Egetis team has done a lot, right? We have been watching them closely. They have done a lot to get the launch going, both in Europe and Germany, where they have launched, as well as in the U.S. They will continue on their path of connecting with patients and caregivers and their physicians. From a deal closure past standpoint, this is a cross-border deal with Sweden where we have issued a tender offer and there is a requirement to achieve 90% approval from shareholders to tender their shares. We have very strong support from the leading shareholders with 42% of shareholders already providing us irrevocables on their shares. We look forward to working to get the necessary, obviously, HSR and Swedish FTC antitrust approval, and other customary closing conditions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day